[HTML][HTML] Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for …
Background Vaccines and prophylactic antibodies against respiratory syncytial virus (RSV)
are in development and likely to be available in the next 5–10 years. The most efficient way …
are in development and likely to be available in the next 5–10 years. The most efficient way …
[HTML][HTML] Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for …
D Cromer, AJ van Hoek, AT Newall, AJ Pollard… - The Lancet Public …, 2017 - Elsevier
Background Vaccines and prophylactic antibodies against respiratory syncytial virus (RSV)
are in development and likely to be available in the next 5–10 years. The most efficient way …
are in development and likely to be available in the next 5–10 years. The most efficient way …
Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for …
D Cromer, AJ van Hoek, AT Newall… - The Lancet. Public …, 2017 - europepmc.org
Background Vaccines and prophylactic antibodies against respiratory syncytial virus (RSV)
are in development and likely to be available in the next 5-10 years. The most efficient way …
are in development and likely to be available in the next 5-10 years. The most efficient way …
[PDF][PDF] Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for …
D Cromer, AJ van Hoek, AT Newall, AJ Pollard, M Jit - Lancet, 2017 - core.ac.uk
Background Vaccines and prophylactic antibodies against respiratory syncytial virus (RSV)
are in development and likely to be available in the next 5–10 years. The most efficient way …
are in development and likely to be available in the next 5–10 years. The most efficient way …
[HTML][HTML] Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for …
D Cromer, AJ van Hoek, AT Newall… - The Lancet Public …, 2017 - thelancet.com
Background Vaccines and prophylactic antibodies against respiratory syncytial virus (RSV)
are in development and likely to be available in the next 5–10 years. The most efficient way …
are in development and likely to be available in the next 5–10 years. The most efficient way …
Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for …
D Cromer, AJ van Hoek, AT Newall… - The Lancet …, 2017 - pubmed.ncbi.nlm.nih.gov
Background Vaccines and prophylactic antibodies against respiratory syncytial virus (RSV)
are in development and likely to be available in the next 5-10 years. The most efficient way …
are in development and likely to be available in the next 5-10 years. The most efficient way …
[引用][C] Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for …
D Cromer, AJ van Hoek, AT Newall, AJ Pollard… - The Lancet Public …, 2017 - cir.nii.ac.jp
Burden of paediatric respiratory syncytial virus disease and potential effect of different
immunisation strategies: a modelling and cost-effectiveness analysis for England | CiNii …
immunisation strategies: a modelling and cost-effectiveness analysis for England | CiNii …
[HTML][HTML] Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for …
D Cromer, AJ van Hoek, AT Newall… - The Lancet. Public …, 2017 - ncbi.nlm.nih.gov
Background Vaccines and prophylactic antibodies against respiratory syncytial virus (RSV)
are in development and likely to be available in the next 5–10 years. The most efficient way …
are in development and likely to be available in the next 5–10 years. The most efficient way …
Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for …
D Cromer, AJ van Hoek, AT Newall… - The lancet Public …, 2017 - researchonline.lshtm.ac.uk
BACKGROUND: Vaccines and prophylactic antibodies against respiratory syncytial virus
(RSV) are in development and likely to be available in the next 5-10 years. The most efficient …
(RSV) are in development and likely to be available in the next 5-10 years. The most efficient …
Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for …
D Cromer, A van Hoek, A Newall, A Pollard… - Lancet. Public health, 2017 - ora.ox.ac.uk
Background Vaccines and prophylactic antibodies against respiratory syncytial virus (RSV)
are in development and likely to be available in the next 5–10 years. The most efficient way …
are in development and likely to be available in the next 5–10 years. The most efficient way …